Compare FKWL & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | CLRB |
|---|---|---|
| Founded | 1981 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 24.5M |
| IPO Year | 1997 | 2008 |
| Metric | FKWL | CLRB |
|---|---|---|
| Price | $2.19 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 7.9K | ★ 159.7K |
| Earning Date | 11-17-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,514,405.00 | N/A |
| Revenue This Year | $32.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.12 | $1.12 |
| 52 Week High | $5.19 | $4.70 |
| Indicator | FKWL | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 35.29 |
| Support Level | N/A | N/A |
| Resistance Level | $2.48 | $3.40 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 44.00 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics. Geographically, it derives revenue from North America, which derives maximum revenue; and Asia.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.